
Chemotherapy is the cornerstone of colorectal cancer treatment, especially for microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer. The FOLFOXIRI triplet regimen (fluorouracil, oxaliplatin, and irinotecan) is an intensive chemotherapy regimen for colorectal cancer, characterized by remarkable efficacy but relatively high toxicity. In 2021, to promote the standardized and rational clinical use of the FOLFOXIRI regimen among Chinese clinicians, the Colorectal Cancer Committee of the China Southwest Oncology Group led a panel of experts in relevant fields. Based on the characteristics of the Chinese population, the mechanisms of the three chemotherapeutic agents, and previous research data, they formulated the "Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer". This consensus proposed the first time the dosage, administration, and adverse event management of the cmFOLFOXIRI regimen, leading to its wide recognition and clinical implementation. Over the five years since the initial consensus was published, multiple key studies have been updated, and numerous new clinical trials based on the FOLFOXIRI regimen have been conducted globally. Meanwhile, the population of patients with colorectal cancer has become increasingly younger, indicating that the modified cmFOLFOXIRI triplet regimen will be applied in more clinical scenarios. Accordingly, the Colorectal Cancer Committee of the China Southwest Oncology Group has led an update of the 2021 Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer. The 2026 edition highlights updated evidence for first-line palliative therapy, conversion therapy, and neoadjuvant therapy; adds expert recommendations on using capecitabine to replace 5-FU in the triplet regimen and recent advances in the use of the triplet regimen for salvage therapy; and provides further information on the tolerability and adverse event management of cmFOLFOXIRI. These updates strengthen the evidence base for the efficacy and safety of the cmFOLFOXIRI regimen and further promote its standardized, precise, and personalized clinical application.
Colorectal cancer (CRC) is one of the most common malignant tumors in China, ranking second in morbidity and fourth in mortality. Metastasis and recurrence are the leading causes of patient death, and the peritoneum is a frequent site of metastasis in CRC, second only to liver and lung metastases. However, the prognosis of peritoneal metastasis is much worse than hepatic and pulmonary metastasis. CRC peritoneal metastasis is challenging early diagnosis, presents with severe symptoms, and has a poor prognosis. It is crucial to emphasize standardized diagnosis and treatment for CRC peritoneal metastasis to improve patients' outcome and enhance their quality of life. This consensus, based on evidence-based medical evidence, revised the "Chinese Expert Consensus on the Diagnosis and Treatment of Colorectal Cancer Peritoneal Metastasis (2022 edition)" and reached a preliminary consensus on the definition, diagnosis, treatment, and prevention of CRC peritoneal metastasis, with the aim of guiding and standardizing the diagnosis and treatment of CRC peritoneal metastasis, developing reasonable and effective comprehensive treatment plans, prolonging survival time and improving quality of life for CRC peritoneal metastasis patients, thereby raising the overall level of diagnosis and treatment for CRC in China.
Circulating tumor cell (CTC), as a novel tumor marker, has the characteristics of non-invasive, dynamic monitoring and high accuracy, and provides precise molecular characteristics of tumors and helps understand the changes in tumor development. Therefore, CTC has important clinical value in the dynamic monitoring of tumor progression. In order to standardize and guide the application of CTC detection in the diagnosis and treatment of gastrointestinal neoplasms, Gastric Cancer Group of Oncology Branch of Chinese Medical Association, Colorectal Cancer Professional Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Gastric Cancer Professional Committee of Chinese Anti-Cancer Association, Digestive Tract Polyp and Precancerous Lesion Professional Committee of Chinese Anti-Cancer Association, jointly convened some domestic experts to discuss and formulate the Chinese expert consensus on the application of circulating tumor cell detection in the diagnosis and treatment of gastrointestinal neoplasms (2023 edition). The consensus provides opinions on the detection technology and clinical application of CTC detection in the diagnosis and treatment of gastrointestinal neoplasms, including the prediction of tumor prognosis, the monitoring of tumor recurrence and metastasis, the evaluation of treatment response, and the additional diagnostic value, providing guidance for clinical application.
2023 年 4 月,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)乳腺癌专家委员会发布了《中国临床肿瘤学会(CSCO)乳腺癌诊疗指南 2023》.新版指南在 2022 年指南的基础上,秉承基于循证医学证据、兼顾药物可及性和结合专家意见的原则进行了更新,保证了指南的科学性及时效性.本文总结新版指南中人表皮生长因子受体 2(human epidermal growth factor receptor 2,HER2)阳性晚期乳腺癌的更新要点,并结合最新循证医学进展和药物可及性变化进行解读.
目的 探讨人类表皮生长因子受体 2(human epidermal growth factor receptor 2,HER2)蛋白表达与肾细胞癌(renal cell carcinoma,RCC)患者临床病理特征的关系及临床意义.方法 收集 2021 年 10 月至 12 月复旦大学附属中山医院收治的 78 例RCC患者的临床资料和手术样本.采用免疫组织化学检查分析样本中的HER2 蛋白表达情况.分析HER2 蛋白表达与患者临床病理特征的关系.结果 78 例RCC患者中HER2 蛋白阳性率为 23.1%(18/78).患者HER2 阳性率在年龄、性别、病理类型、国际泌尿系统病理学会/世界卫生组织(International Society of Urological Pathology/World Health Organization,ISUP/WHO)分级、T分期、年龄和性别方面比较,差异均无统计学意义(均P>0.05).结论 RCC中HER2 高表达与病理类型、ISUP/WHO分级和T分期等临床特征无关.